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Non-canonical NFκB activation 
promotes chemokine expression in 
podocytes
Lara Valiño-Rivas1,2, Laura Gonzalez-Lafuente1,2, Ana B. Sanz1,2, Marta Ruiz-Ortega1,2, 
Alberto Ortiz1,2,* & Maria D. Sanchez-Niño1,2,*
TNF-like weak inducer of apoptosis (TWEAK) receptor Fn14 is expressed by podocytes and Fn14 
deficiency protects from experimental proteinuric kidney disease. However, the downstream effectors 
of TWEAK/Fn14 in podocytes are poorly characterized. We have explored TWEAK activation of 
non-canonical NFκB signaling in cultured podocytes. In cultured podocytes, TWEAK increased the 
expression of the chemokines CCL21, CCL19 and RANTES in a time-dependent manner. The inhibitor of 
canonical NFκB activation parthenolide inhibited the CCL19 and the early RANTES responses, but not 
the CCL21 or late RANTES responses. In this regard, TWEAK induced non-canonical NFκB activation 
in podocytes, characterized by NFκB2/p100 processing to NFκB2/p52 and nuclear migration of RelB/
p52. Silencing by a specific siRNA of NIK, the upstream kinase of the non-canonical NFκB pathway, 
prevented CCL21 upregulation but did not modulate CCL19 or RANTES expression in response to 
TWEAK, thus establishing CCL21 as a non-canonical NFκB target in podocytes. Increased kidney Fn14 
and CCL21 expression was also observed in rat proteinuric kidney disease induced by puromycin, 
and was localized to podocytes. In conclusion, TWEAK activates the non-canonical NFκB pathway in 
podocytes, leading to upregulation of CCL21 expression. The non-canonical NFκB pathway should be 
explored as a potential therapeutic target in proteinuric kidney disease.
Chronic kidney disease (CKD) is one the three causes of death that most increased worldwide from 1990 to 
20131,2. CKD is now categorized based on glomerular filtration rate and degree of albuminuria, since albuminuria, 
a marker of podocyte injury, is a key risk factor for death and for progression of CKD. Proteinuric kidney diseases, 
such as diabetic kidney disease and chronic glomerulopathies, remain the most frequent causes of CKD, despite 
the availability of antiproteinuric agents such as renin-angiotensin system blockers3. Thus, there is an increasing 
interest in understanding the molecular mechanisms of podocyte injury or activation to express inflammatory 
mediators that may contribute to proteinuric kidney disease. Recently, functional in vivo studies identified the 
TNF superfamily cytokine Tumor necrosis factor-like weak inducer of apoptosis (TWEAK, Apo3L or TNFSF12) 
as a key contributor to proteinuric kidney disease in the context of immune-complex deposition (lupus nephritis, 
anti-glomerular basement membrane disease) and in the absence of immune-mediated injury (protein over-
load)4–8. Fn14-knockout MRL-lpr/lpr mice were protected from glomerular injury and glomerular podocytes 
were preserved5. Based on this preclinical data, clinical trials are testing the hypothesis that anti-TWEAK neu-
tralizing antibodies are nephroprotective in human lupus nephritis4. However, TWEAK actions on podocytes 
have been poorly characterized. TWEAK signaling directly damaged barrier function and increased filtration 
through podocyte monolayers5, induced cell motility9 and promoted inflammatory responses in podocytes8. In 
this regard, the podocyte contribution to glomerular inflammation has recently been emphasized10–12. Thus, we 
have now explored further actions of TWEAK in podocytes. Specifically, we have focused on the regulation of 
the activation of the pro-inflammatory transcription factor nuclear factor-kappa B (NFκ B) in podocytes13,14, 
since unravelling this pathway may provide new possibilities for development of therapeutic approaches for pro-
teinuric kidney disease. Like TNF, TWEAK activates canonical NFκ B signaling in diverse cell types, including 
podocytes8,15,16. Unlike TNF, TWEAK promotes the non-canonical activation of NFκ B in splenocytes and tubu-
lar cells14,17. In tubular cells, TWEAK-induced non-canonical NFκ B activation led to expression of CCL21, a 
chemokine previously described as a transcriptional target of non-canonical NFκ B activation in splenocytes18. 
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However, little is known of non-canonical NFκ B activation in podocytes (reviewed in ref. 14). Interestingly, podo-
cyte CCL21 was reported to contribute to the podocyte-mesangial cell crosstalk by activating CCR7 receptors in 
mesangial cells and promoting mesangial cell survival, proliferation, migration and matrix adhesion through 
activation of glycogen synthase kinase-3 (GSK-3), protein kinase B (PKB/Akt) and integrin-linked kinase19–21. 
While CCL21-induced mesangial cell proliferation was initially hypothesized to contribute to glomerular home-
ostasis, the hypothesis was not tested and several glomerulonephritis are characterized by mesangial prolifera-
tion. Furthermore, kidney CCL21 expression was associated to recurrence of original nephropathy among renal 
transplant patients22 and to acute rejection in zero-hour biopsies from deceased donor kidneys23, and was hypoth-
esized to facilitate alloreactive immune responses in renal transplant recipients24. Moreover, anti-CCL21 anti-
bodies reduced kidney fibrosis and inflammation through inhibition of fibrocyte recruitment25. Thus, functional 
in vivo preclinical studies are consistent with a detrimental role of CCL21 in kidney fibrosis and inflammation. 
CCL21 expression by podocytes could thus be chemotactic or elicit detrimental biological responses in mesangial 
or tubular cells. However, the factors regulating CCL21 expression in podocytes have not been characterized.
We have now explored whether TWEAK modulates CCL21 expression in podocytes and the role of 
non-canonical NFκ B activation in the process. Furthermore, we have explored the expression of the TWEAK 
receptor and CCL21 in experimental proteinuric kidney disease.
Results
TWEAK increases CCL21 expression in cultured podocytes and this response is independent 
from canonical NFκB activation. The time-course of TWEAK-induced chemokine expression differed 
between cultured podocytes and tubular cells15,17. This may imply differential involvement of different NFκ B 
activation pathways. TWEAK-induced mRNA expression of the non-canonical NFκ B target CCL21 progres-
sively increased over 24 h in podocytes (Fig. 1A) as was observed for tubular cells17. TWEAK also increased the 
expression of CCL19 mRNA, which is also a target of non-canonical NFκ B activation in splenocytes26,27 (Fig. 1B). 
However, unlike the similar time-course observed for TWEAK-induced CCL21 and CCL19 expression in tubular 
cells17, the time-course of CCL19 and CCL21 expression differed in podocytes. Thus, CCL19 expression peaked 
at 6 h and was already decreasing at 24 h (Fig. 1B). TWEAK also increased RANTES mRNA expression progres-
sively for up to 24 h (Fig. 1C). This is in contrast to tubular cells, in which TWEAK-induced RANTES expression 
peaks at 6 h, as expected for a canonical NFκ B target, and then decreases15. Increased protein levels in cell lysates 
was also noted (Fig. 1D).
Parthenolide inhibits Iκ Bα degradation and RelA nuclear translocation and thus, canonical NFκ B activa-
tion15,28. In previous studies, we observed that parthenolide inhibited RelA nuclear translocation induced by 
TWEAK in podocytes as well as the expression of the canonical RelA target gene MCP-18. However, parthenolide 
did not prevent CCL21 mRNA or protein up-regulation induced by TWEAK (Fig. 2A,B) suggesting that RelA 
does not mediate CCL21 transcription. By contrast, parthenolide did prevent the upregulation of CCL19 mRNA 
in podocytes (Fig. 2C), suggesting the involvement of different pathways for NFκ B activation in the regulation of 
both chemokines in podocytes, in contrast to prior reports in splenocytes18,26. Parthenolide prevented the early, 
but not the late increase in RANTES mRNA expression (Fig. 2D), suggesting the contribution of canonical but 
also of parthenolide-resistant pathways to TWEAK-induced RANTES upregulation in podocytes. Similar results 
were observed using the NF-κ B inhibitor BAY 11-7085 (Suppl. Fig. 1).
TWEAK induces non-canonical NFκB activation in cultured podocytes. In previous studies we 
observed that TWEAK induced a sustained increase in NFκ B DNA-binding activity in podocytes that peaked 
at 24 h as assessed by electrophoretic mobility shift assay (EMSA)8. This sustained increase is consistent with 
non-canonical NFκ B activation, since canonical NFκ B is a transient phenomenon, but non-canonical NFκ B acti-
vation in response to TWEAK in other epithelial cells, such as tubular cells, increases progressively up to 24 h13. 
The non-canonical NFκ B pathway requires activation of NFκ B-inducing kinase (NIK), that phosphorylates IKKα 
and serves as a docking molecule that recruits IKKα to NFκ B2 p100, facilitating NFκ B2 p100 ubiquitination and 
subsequent proteasomal processing into the mature NFκ B2 p52 subunit, allowing RelB/p52 complexes to enter 
the nucleus14. TWEAK induces NFκ B2 p100 processing to NFκ B2 p52 (Fig. 3A) as well as p52/RelB nuclear 
translocation in cultured podocytes in a time-dependent manner (Fig. 3B,C). These results indicate that TWEAK 
induces non-canonical, sustained NFκ B activation in podocytes. To explore the role of non-canonical NFκ B 
activation in the regulation of TWEAK-induced chemokine expression, we silenced NIK using a specific siRNA 
(Fig. 4A). NIK silencing prevented CCL21 upregulation in cultured podocytes (Fig. 4B,C) but did not modulate 
CCL19 or RANTES expression (Fig. 4D,E). This suggests that CCL21 is a non-canonical NFκ B pathway target in 
podocytes, but other chemokines are not.
Increased podocyte CCL21 in experimental proteinuric kidney disease. We next explored 
the expression of the chemokine identified as a non-canonical NFκ B target, CCL21, during podocyte injury 
and by podocytes in vivo. For assessment of CCL21 expression in proteinuric kidney disease we chose a 
non-immunological model of podocyte injury, rat PAN nephrosis, since it is directly induced by a podocyte 
toxin, does not require activation of the immune system and is representative of human focal segmental glomeru-
losclerosis, a common human proteinuric nephropathy29,30. Systemic PAN administration causes podocyte injury 
in rats, leading to increased urinary protein excretion by day 2 and full-blown nephrotic syndrome at day 10. 
Increased whole kidney TWEAK receptor (Fn14) mRNA (Fig. 5A) and protein (Fig. 5B,C) expression was noted 
in PAN-injected rats 2 and 10 days post-injection. Moreover, CCL21 mRNA (Fig. 5D) and protein (Fig. 5C,E) 
was also increased, following a similar time-course. Immunohistochemistry confirmed Fn14 and CCL21 pro-
tein expressing cells co-localized with the podocyte-specific maker WT-1 in glomeruli of PAN-injected rats 
(Fig. 6 and Suppl. Fig. 2).
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To better understand the relationship between podocyte injury and expression of inflammatory molecules, we 
tested the regulation of Fn14 and CCL21 expression by PAN or by high glucose in cultured podocytes. Either a 
cytotoxic concentration of PAN or high glucose levels increased Fn14 and CCL21 mRNA (Suppl. Fig. 3) expres-
sion in cultured podocytes.
Discussion
TWEAK had previously been shown to have a proinflammatory effect dependent on canonical NFκ B activation 
in podocytes, leading to the synthesis of the MCP-1 chemokine8,31. We now show that TWEAK also activates the 
non-canonical NFκ B pathway in podocytes, promoting the expression of the chemokine CCL21 that, as Fn14, is 
upregulated in vivo in the course of nephrotoxic podocyte injury.
NFκ B activates the transcription of different genes with specificity and kinetics that vary in a gene-, stimulus- 
and cell-specific manner. Delayed kinetics of gene transcription may be due to involvement of the non-canonical 
NFκ B pathway or to decreased DNA accessibility to the canonical NFκ B pathway. The later has been described 
for RANTES in tubular cells and other cell types13,15. We have now focused on understanding the regulators and 
targets of non-canonical NFκ B activation in podocytes in response to TWEAK, a cytokine that promotes glo-
merular injury in experimental animals and is currently the target of clinical trials in human glomerular disease.
Some actions of TWEAK in podocytes had been previously characterized, including damage to the bar-
rier function5, motility9 and inflammatory responses as a consequence of canonical NFκ B activation leading 
to MCP-1 synthesis8. These observations may underlie the causative role of TWEAK in glomerular injury4,32. 
Figure 1. TWEAK upregulates chemokine mRNA and protein expression in podocytes: differences in 
time-course. Podocytes were treated with 100 ng/mL TWEAK. (A) Time-course of CCL21 mRNA induction. 
* p < 0.004 vs control. (B) Time-course of CCL19 mRNA induction. * p < 0.002 vs control. (C) Time-course 
of RANTES mRNA induction. * p < 0.003 vs control. Expression of mRNA was assessed by real time RT-PCR. 
Mean ± SEM of three independent experiments. (D) Representative Western blot of CCL21, CCL19 and 
RANTES protein in cell lysates.
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Interestingly, in podocytes TWEAK induced sustained NFκ B activation as assessed by EMSA8, although the 
molecular basis for the sustained NFκ B activation was not explored. We now provide evidence that in podo-
cytes TWEAK recruits sequentially the canonical and non-canonical pathways of NFκ B activation, resulting 
in the transcription of different sets of chemokines. Initially canonical activation of RelA promotes the release 
of MCP-18, and as identified here, the gene expression of RANTES and CCL19, followed by activation of the 
non-canonical NFκ B pathway requiring NIK, NFκ B2 p100 processing and migration of NFκ B2 p52/RelB to 
nuclei that promotes synthesis of CCL21. The transient nature of chemokine protein expression in cell lysates 
Figure 2. Targeting canonical NFκB activation modulates RANTES and CCL19 but not CCL21 expression in 
podocytes. Podocytes were treated with 100 ng/mL TWEAK. (A) CCL21 mRNA. * * p < 0.001 vs control. * p < 0.01 
vs TWEAK 24 h. (B) CCL21 protein at 24 h (Western blot). (C) CCL19 mRNA.* p < 0.001 vs control. * * p < 0.01 vs 
TWEAK 24 h. (D) RANTES mRNA. * p < 0.01vs Control, * * p < 0.009 vs TWEAK 24 h. Expression of mRNA was 
assessed by real time RT-PCR and protein by Western blot. Mean ± SEM of three independent experiments.
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(3 h for CCL19, 3–6 h for RANTES) may be due to either posttranscriptional regulatory mechanisms or secretion 
of the chemokine into the cell culture medium. Thus, CCL21 is identified as a TWEAK- and non-canonical NFκ B 
pathway-regulated gene in podocytes. In this regard, podocytes differ from splenocytes, which were reported to 
require non-canonical NFκ B activation by LTβ R ligation to upregulate both CCL21 and CCL1933.
TWEAK induced non-canonical NFκ B activation in fibroblasts34 and in kidney tubular cells17, but it was 
unknown whether the pathway is active in podocytes. Information on non-canonical NFκ B targets has been 
detailed for lymphoid cells. Thus, LTβ R activation of the non-canonical NFκ B pathway induces CCL21, CCL19, 
CXCL12, CXCL13, and TNFSF13b (BAFF/BLYSS) expression in the spleen33. Of these potential NFκ B2 targets, 
Figure 3. TWEAK induces NFκB2/p100 processing to NFκB2/p52 and nuclear translocation of NFκB2/
p52 and RelB in cultured podocytes. (A) Western blot and quantification. Note disappearance of p100 from 
1 hour onwards and concomitant appearance of the p52 band. Mean ± SEM of three independent experiments. 
* p < 0.05 vs control. (B) Confocal microscopy of NFκ B2 (green), nuclei counterstained with DAPI (blue); and 
(C) Confocal microscopy of RelB (red), nuclei counterstained with DAPI (blue). NFκ B2 and RelB progressively 
increased in podocyte nuclei from 3 to 24 hours of TWEAK stimulation.
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we chose CCL19 and CCL21 for further study in podocytes, together with RANTES, a representative of genes 
with a delayed response to canonical NFκ B activation in other cell types. Only CCL21 was regulated by the 
non-canonical NFκ B target in podocytes. TWEAK-induced increased CCL21 mRNA was delayed with respect 
to other chemokines and persistent. This contrasts to the earlier peaks of MCP-18, RANTES and CCL19 which 
were abolished by RelA inhibitors. The delayed induction of CCL21 is dependent on the delayed activation of the 
non-canonical NFκ B pathway that requires NIK. To the best of our knowledge CCL21 is the first non-canonical 
Figure 4. NIK targeting prevents TWEAK-induced CCL21 but not CCL19 expression in cultured 
podocytes. (A) NIK siRNA downregulates NIK protein and mRNA expression. * p < 0.005 vs Scramble siRNA. 
(B) NIK siRNA prevents the upregulation of CCL21 mRNA in response to TWEAK. (C) NIK siRNA prevents 
the upregulation of CCL21 protein in response to TWEAK at 24 h. (D) NIK siRNA does not prevent the 
upregulation of CCL19 mRNA in response to TWEAK. (E) NIK siRNA does not prevent the upregulation of 
RANTES mRNA in response to TWEAK. Expression of mRNA was assessed by real time RT-PCR and protein 
by Western blot. Mean ± SEM of three independent experiments, * p < 0.005 vs Scramble siRNA, * * p < 0.005 vs 
Scramble siRNA+ TWEAK.
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NFκ B2 target identified in podocytes. The in vivo observation of increased CCL21 and Fn14 expression in exper-
imental proteinuric kidney disease suggests that this might be a clinically relevant observation.
Interestingly, differences were apparent between the pathways for NFκ B activation and the time-course of 
chemokine expression between podocytes and tubular cells and splenocytes15,17,26,27 (Fig. 7). This argues for 
podocyte-specific mechanism regulating chemokine expression and for the need to understand the precise 
molecular mechanisms involved in the regulation of podocyte inflammatory responses, since not all observations 
in other renal cell types apply to podocytes. This offers the opportunity for differential manipulation of inflamma-
tory responses in a cell type-specific fashion in the kidneys.
CCL21 is a high affinity ligand for chemokine receptor 7 (CCR7). Activation of CCR7 is chemotactic for thy-
mocytes, T cells, mature dendritic cells, and, to a lesser extent, B cells35. CCL21 mediates homing of lymphocytes 
Figure 5. Fn14 and CCL21 mRNA and protein upregulation in PAN nephrosis. (A) Whole kidney Fn14 
mRNA expression. qRT-PCR. (B) Whole kidney Fn14 protein expression. Quantification of Western blot. 
(C) Whole kidney Fn14 and CCL21. Western blot. (D) Whole kidney CCL21mRNA expression. qRT-PCR. 
(E)Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, * p < 0.05 
vs vehicle, * * p < 0.001 vs vehicle.
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to secondary lymphoid organs, attracts CCR7-positive fibrocytes to injured kidneys and induces chemotaxis and 
proliferation of mesangial cells19,25. In this regard, podocytes expression of CCL21 activated CCR7 receptors in 
mesangial cells19–21. According to the Nephromine (http://www.nephromine.org/) database that integrates tran-
scriptomics data from several published sources, glomerular CCL21 mRNA was increased in human collapsing 
FSGS (fold change 1.591, p = 0.045), diabetic nephropathy (1.477, p = 0.023), lupus nephritis (1.316, p = 0.034) 
and IgA nephropathy (1.137, p = 0.040) and a trend was observed in FSGS (1.386, p = NS) when compared to 
normal glomeruli (http://www.nephromine.org/; accessed September 1, 2015)36–39. This suggests that experimen-
tal findings have implications for human proteinuric kidney disease. However, the factors that regulate podocyte 
CCL21 expression had not been identified.
In conclusion, TWEAK is an activator of the non-canonical NFκ B pathway in podocytes, and the chemokine 
CCL21 is activated through this pathway while CCL19 or RANTES are not. To our knowledge this is the first 
time that stimuli modulating non-canonical NFκ B activation and gene targets have been described in podo-
cytes. Activation of the non-canonical NFκ B pathway may contribute to the deleterious effect of TWEAK in 
Figure 6. Fn14 and CCL21 upregulation in PAN nephrosis. Immunohistochemistry. (A) Fn14 and (B) CCL21 
immunohistochemistry 10 days following PAN or vehicle injection. Note expression of Fn14 and CCL21 by 
WT1 positive (blue) podocytes (arrow) in PAN-treated rats (arrows). Original magnification x400. Detail 
x1000. Images representative of 6/7 animals per group.
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proteinuric kidney disease, as Fn14 knockout mice were protected from proteinuric kidney injury of immune and 
non-immune origin5,8 and should be explored as a therapeutic target itself.
Material and Methods
Cells and reagents. Conditionally immortalized mouse podocytes were a kind gift by Peter Mundel and 
were cultured as described40. Podocytes were propagated on type I collagen (Biochrom, Berlin, Germany) at 33 °C 
in the presence of 10 U/mL mouse recombinant interferon (IFN-γ ) (Immugenex, Los Angeles, CA) (permissive 
conditions) to enhance expression of a thermosensitive T antigen. Once cells had reached 70 to 80% confluence, 
differentiation and a quiescent phenotype was induced by culture under “non-permissive conditions” at 37 °C 
without IFN-γ for >12 days, resulting in disappearance of T antigen. Culture medium was RPMI 1640 (GIBCO, 
Grand Island, NY) with 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin 
and 100 μ g/mL streptomycin. For experiments cells were cultured in serum-free media 24 hours previous to 
stimulation and throughout the experiment.
Recombinant human soluble TWEAK (Alexis, Läufelfingen, Switzerland) was used at 100 ng/ml based on 
prior TWEAK dose-response studies in renal cells8. The NFκ B inhibitors parthenolide (Sigma, St. Louis, MO) 
and Bay 11-7085 (R&D Systems, Minneapolis, MN) were used at 10 μ M based on previous dose-responses 
studies in cultured podocytes8. Puromycin aminonucleoside (PAN) (Sigma, St. Louis, MO) was used at a 
concentration of 100 μ g/mL. In preliminary experiments, this concentration was found to be cytotoxic to 
Figure 7. Differential involvement of NFκB activation pathways in the regulation of chemokine expression 
in renal tubular cells and podocytes. In splenocytes, both CCL19 and CCL21 are transcriptional targets of 
the non-canonical pathway for NFκ B activation involving NFκ B2/RelB heterodimers18. (A) Murine renal 
tubular cells15,17. TWEAK-induced RANTES expression is inhibited by parthenolide, suggesting canonical 
NFκB activation. By contrast, CCL21 expression is prevented by NIK siRNA, but not by parthenolide. While 
not specifically studied by functional inhibitors, the time-course of CCL19 expression and the fact that CCL19 
was upregulated by TWEAK but not by TNF suggests that CCL19 is a transcriptional target for non-canonical 
NFκ B activation in tubular cells. (B) Podocytes. Note the different time-course of TWEAK-induced RANTES 
and CCL19 mRNA expression between tubular cells and podocytes. The increased CCL19 mRNA and the early 
increase in RANTES mRNA is inhibited by parthenolide, suggesting dependence on canonical NFκ B activation. 
CCL21 is the only chemokine that depends on non-canonical NFκ B activation in splenocytes, tubular cells and 
podocytes. The late increase of RANTES mRNA expression in podocytes could not be inhibited by targeting 
the canonical or non-canonical pathways suggesting NFκ B-independence or activation of alternative NFκ B 
pathways13,15.
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podocytes in culture. For high glucose experiments, glucose was added in the media to reach a final concentra-
tion of 700 mg/dl versus control media with 200 mg/dl glucose41.
Western blot. Western blots were performed as described previously41. Primary antibodies were rabbit poly-
clonal anti-Fn14 antibody (1:1000, Cell Signaling, Hertfordshire, UK), rabbit polyclonal anti-p100/52 (1:500, Cell 
Signaling), rabbit polyclonal anti-CCL21 (1:500, Santa Cruz), goat polyclonal anti-CCL19 (1:500, R&D Systems), 
RANTES (1:500, Acris) and anti-NIK (1:500, Santa Cruz). Since chemokines were assessed in cell lysates, part of 
the protein would have been expected to be secreted, especially at later time points. Blots were then probed with 
anti-α -tubulin (1:2000, Sigma) and levels of expression were corrected for minor differences in loading.
Quantitative reverse transcription-polymerase chain reaction. One μ g RNA isolated by Trizol 
(Invitrogen UK) was reverse transcribed with High Capacity cDNA Archive Kit and real-time PCR was per-
formed on a ABI Prism 7500 PCR system (Applied Biosystems, Foster City, CA) using the DeltaDelta Ct method. 
Expression levels are given as ratios to GAPDH. Pre-developed primer and probe assays were from Applied41.
siRNA transfection. Cells were seeded at a 3 × 105 in 6-wells plates and transfected with 25 nM NIK siRNA 
(Santa Cruz), Opti-MEM I Reduced Serum Medium and Lipofectamine 2000 (Invitrogen)42. After 18 h, trans-
fected cells were washed and cultured for 24 hours in complete medium, stimulated with 100 ng/mL TWEAK 
for 24 h and harvested for analysis. This time point was selected from a time-course of decreasing NIK protein 
expression in response to siRNA. A negative control scrambled siRNA provided by the manufacturer did not 
reduce NIK protein.
Immunohistochemistry. Immunohistochemistry was carried out as previously described on paraffin- 
embedded 5 μ m tissue sections43. Primary antibodies were rabbit polyclonal anti-CCL21 (1:75), rabbit polyclonal 
anti-Fn14 (1:50, Santa Cruz) and anti-WT1 (Dako, Denmark). Negative controls included incubation with a 
non-specific immunoglobulin of the same isotype as the primary antibody. Sections were counterstained with 
Carazzi’s hematoxylin.
Confocal microscopy. Cells plated onto Labtek™ slides were fixed in 4% paraformaldehyde and perme-
abilized in 0.2% Triton X-100 in PBS for 10 min each. After washing in PBS, cells were incubated overnight at 
4 °C with rabbit polyclonal anti-p52 or anti-RelB antibody (1:100), followed by incubation with anti-rabbit Alexa 
Fluor 488 or 633 (1:300, Invitrogen). After washing, cells were mounted in 70% glycerol in PBS, and analyzed with 
a DM-IRB confocal microscope (Leica DM, Bannockburn, IL)31. Nuclei cells were stained with DAPI (Vector 
Laboratories, Inc., Burlingame, CA) to observe the typical morphological changes.
Animal model. Two groups of 10-week-old Wistar Kyoto rats (Criffa, Barcelona, Spain) were studied (n = 9/
group). Nephrosis was induced by a single i.v. injection of 150 mg/Kg puromycin aminonucleoside (PAN, 
Sigma)29,30. Control rats received saline vehicle. Rats were sacrificed at days 2 and 10 after injection. To determine 
urinary protein level, rats were placed into metabolic cages 0, 2, and 10 days after PAN injection. Twenty-four 
hour urine samples were collected in brown bottles and total urinary protein was measured. Proteinuria was 
4.8 ± 0.9 mg/d in control rats, 8.0 ± 2.0 mg/d in PAN-injected rats at day 2 and 203.7 ± 44.4 mg/d in PAN-injected 
rats at day 10; and serum creatinine 0.40 ± 0.01 mg/dl in control rats, 0.47 ± 0.03 mg/dl in PAN-injected rats at 
day 2 and 0.61 ± 0.05 mg/dl in PAN injected rats at day 10.
Kidneys were perfused in situ with cold saline before removal. One kidney from each rat was fixed in buffered 
formalin, embedded in paraffin and used for immunohistochemistry. The other kidney was snap-frozen in liquid 
nitrogen for RNA and protein studies. Before sacrifice, animals were placed in metabolic cages for 24 h urine 
collection and albuminuria determination by ELISA, using rat albumin as a standard (Celltrend, Luckenwalde, 
Germany). All experimental procedures were approved by the Animal Care and Use Committee of the Institution 
IIS-Fundacion Jimenez Diaz, according to the guidelines for ethical care of the European Community.
Statistics. Statistical analysis was performed using SPSS 11.0 statistical software. Results are expressed as 
mean ± SEM. Significance at the p < 0.05 level was assessed by Student´s t test for two groups of data and ANOVA 
for three of more groups.
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